Pacific Edge (PEB.NZ) slumps 89.9% on Novitas decision.
Key Takeaways. Extended Summary: Pacific Edge’s stock plummeted by 89.9% following the announcement that Medicare coverage of Cxbladder tests in the US would cease from July 17. After a temporary halt, trading resumed at a mere 5 cents per share, down from 49.5 cents. This drastic decline resulted in a